Pharma Five is a registered firm based in India. We specialize in Named Patient Imports, Imported cancer drugs, Imported medicines in india.
Contact Us Pharma Five Door No. 74, Old No. 26, Fagun Mansion, 3rd Floor, Ethiraj Salai, Egmore, Chennai - 600008 +916374297988 info@pharmafive.org
Medicine name : Lyrfigtu
Generic name : Lirafugratinib
Manufactured By : Elevar Therapeutics, Inc.
Indications : Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Medicine Description : A targeted therapy for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. Lyrfigtu (Lirafugratinib) is an oral kinase inhibitor that selectively targets FGFR2, a protein involved in cancer cell growth and survival. By blocking abnormal FGFR2 signaling, it helps inhibit the growth and proliferation of cancer cells. It is used for eligible adult patients whose cancer has progressed following previous systemic treatment.
Lyrfigtu (Lirafugratinib) is a targeted anticancer medicine used to treat adults with previously treated, unresectable or metastatic cholangiocarcinoma containing FGFR2 gene fusions or rearrangements.
Lyrfigtu works by selectively blocking FGFR2 proteins that contribute to cancer-cell growth and survival, helping slow the progression of bile duct cancer.
Lyrfigtu is prescribed for adults with previously treated, unresectable, locally advanced or metastatic FGFR2-positive cholangiocarcinoma.
Take Lyrfigtu orally once daily as prescribed. Swallow the capsules whole without opening, crushing or chewing them.
Common side effects include nail problems, hand-foot skin reactions, mouth sores, hair loss, dry eyes, dry mouth, fatigue, taste changes, constipation and dry skin.
Yes. Serious side effects may include retinal problems, vision changes, high phosphate levels, tissue calcification and bleeding. Contact your doctor if concerning symptoms occur.
Continue taking Lyrfigtu until your cancer progresses or side effects become unacceptable, as determined by your treating doctor.
Consult your doctor before drinking alcohol during treatment. Avoid excessive alcohol consumption.
Lyrfigtu may harm an unborn baby. Effective contraception is recommended during treatment and for 6 months after the last dose for women who can become pregnant.
Lyrfigtu may interact with certain medicines, including CYP3A inducers and medicines affected by drug transporters. Inform your doctor about all medicines and supplements you take.
If you miss a dose, take it within 4 hours of the scheduled time. If more than 4 hours have passed, skip the missed dose and take the next dose at the usual time. Do not take an extra dose.
Yes. Lyrfigtu can be taken with or without food. Take it consistently as directed by your doctor.
Attend regular eye examinations and blood tests, especially phosphate monitoring. Inform your doctor about other medicines and report vision changes or unusual bleeding promptly.
Store Lyrfigtu at 20°C to 25°C, with permitted excursions between 15°C and 30°C. Keep it in its original packaging and protect it from moisture.
Pharma Five may assist patients seeking Lyrfigtu through medicine import support, subject to applicable regulations and required medical documentation. Pharma Five assists in its procurement.